company background image
1789 logo

ScinoPharm Taiwan TWSE:1789 Stock Report

Last Price

NT$26.85

Market Cap

NT$21.2b

7D

-2.2%

1Y

-14.2%

Updated

18 Jul, 2024

Data

Company Financials

ScinoPharm Taiwan, Ltd.

TWSE:1789 Stock Report

Market Cap: NT$21.2b

1789 Stock Overview

Researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, Taiwan, and internationally.

1789 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends1/6

Rewards

Risk Analysis

No risks detected for 1789 from our risk checks.

ScinoPharm Taiwan, Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ScinoPharm Taiwan
Historical stock prices
Current Share PriceNT$26.85
52 Week HighNT$34.05
52 Week LowNT$24.30
Beta0.33
11 Month Change-7.73%
3 Month Change0.37%
1 Year Change-14.22%
33 Year Change4.47%
5 Year Change6.76%
Change since IPO-39.05%

Recent News & Updates

ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 17
ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Recent updates

ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 17
ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First

Apr 04
Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First

A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Mar 14
A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock

Feb 21
Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock

ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares

Jan 25
ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares

We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease

Jan 04
We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease

Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Dec 14
Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?

Nov 23
Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?

Shareholder Returns

1789TW PharmaceuticalsTW Market
7D-2.2%1.8%-0.9%
1Y-14.2%15.4%37.3%

Return vs Industry: 1789 underperformed the TW Pharmaceuticals industry which returned 15.4% over the past year.

Return vs Market: 1789 underperformed the TW Market which returned 37.3% over the past year.

Price Volatility

Is 1789's price volatile compared to industry and market?
1789 volatility
1789 Average Weekly Movement3.1%
Pharmaceuticals Industry Average Movement4.5%
Market Average Movement4.7%
10% most volatile stocks in TW Market8.5%
10% least volatile stocks in TW Market2.2%

Stable Share Price: 1789 has not had significant price volatility in the past 3 months.

Volatility Over Time: 1789's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997n/aSusan Luwww.scinopharm.com

ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, Taiwan, and internationally. The company offers small molecular drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates.

ScinoPharm Taiwan, Ltd. Fundamentals Summary

How do ScinoPharm Taiwan's earnings and revenue compare to its market cap?
1789 fundamental statistics
Market capNT$21.23b
Earnings (TTM)NT$385.07m
Revenue (TTM)NT$3.42b

55.1x

P/E Ratio

6.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1789 income statement (TTM)
RevenueNT$3.42b
Cost of RevenueNT$2.10b
Gross ProfitNT$1.33b
Other ExpensesNT$940.34m
EarningsNT$385.07m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.49
Gross Margin38.74%
Net Profit Margin11.26%
Debt/Equity Ratio0.2%

How did 1789 perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

62%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.